Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years

NCT03382964 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT03382964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03382964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years
Lead sponsor
Valneva Austria GmbH
Phase
Phase 1
Overall status
Completed
Start date
March 5, 2018
Completion date
July 28, 2019
Enrollment
120 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya